Clovis Oncology Inc
Most Recent
Why Portola Pharmaceuticals’ Stock Price Is Plummeting Today
Today, Portola Pharmaceuticals is trading at $19.32, which is a ~7.52% decline from yesterday’s close of $20.89 on December 10.
Why Clovis Oncology Stock Rose 48% in November
On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30.
Gauging Analysts’ Views on Clovis Stock
In November, of the 12 analysts covering Clovis Oncology (CLVS) stock, seven have given it “buy” or higher ratings, and five have given it “hold” ratings.
How Clovis Oncology Is Positioned in November
Clovis Oncology generated total revenue of $22.76 million in the third quarter compared to $16.81 million in the comparable period of 2017.
Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results
On November 8, after Portola Pharmaceuticals released its third-quarter financial results, the stock price rose 21.41%.
Here’s What’s Driving Investor Interest in Immunomedics
Clinical stage biopharmaceutical company Immunomedics (IMMU) is currently focused on advancing several research programs.
Exact Sciences: Why the Stock Price Is Soaring
On August 22, Exact Sciences (EXAS) is trading at a stock price of $62.95, which represents ~25.78% growth from the close of $50.05 on August 21.
Here’s What Tesaro’s Valuation Trend Indicates
Tesaro stock has been on a downward trajectory for the past 52 weeks. From a high of $135 on September 5, 2017, it has corrected to $27 in August.
Analyst Recommendations for Exelixis in August
In the second quarter, Exelixis’s (EXEL) cabozantinib franchise generated revenues of $145.8 million, a 66% YoY growth.
What to Expect from Clovis Oncology’s Q2 2018 Earnings
Biopharmaceutical company Clovis Oncology (CLVS) is expected to report its second-quarter earnings on August 1.
Tesaro Stock Up over 16% on Rumors of Acquisition by Roche
Yesterday, Tesaro (TSRO) stock rose ~16.3%, triggered by rumours of an acquisition bid by Roche (RHHBY), which registered a stock price rise of ~2.1%.
A Look at Clovis Oncology’s Clinical Programs
The FDA’s approval of Clovis Oncology’s (CLVS) Rubraca for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in April was the second and much broader indication the drug has been approved for.
A Review of Clovis Oncology’s Financial Performance
In the first quarter, Clovis Oncology’s (CLVS) product revenue rose YoY (year-over-year) to $18.5 million from $7 million.
How Lynparza Performed in 1Q18
On July 27, Merck (MRK) and AstraZeneca (AZN) announced a strategic global collaboration for co-developing and co-commercializing the latter’s poly ADP ribose polymerase (or PARP) inhibitor, Lynparza.
AstraZeneca’s Lynparza Witnessed High Growth in 2017
In 4Q17, AstraZeneca’s (AZN) Lynparza reported revenues of $100.0 million, which reflected ~61.0% growth on a year-over-year basis.
Gilead Sciences on the Street: Analyst Recommendations in October
Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy.”
Analysts’ Recommendations for Bristol-Myers Squibb in August 2017
Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts recommended a “sell.”
Is Rising Consumer Sentiment Helping the Market Rally in 2017?
The S&P 500 Index (SPX-INDEX) has posted a rise of ~5% since the beginning of 2017, with banks and energy stocks leading the rally as of March 29, 2017.
IBB Small-Caps Reduce Negative Returns in December
The small-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) rose 1.4% on December 21, 2015, and reduced the negative returns.
Immunogen Topped the Small-Cap Stocks with High Volumes
Immunogen rose by 7.2% as of November 25, 2015. The stock rose on the high trading volume. It closed at $13.76. It passed the 100-day moving average price.
Pacira’s Strong 3Q15 Results Helped the Pharma Subgroup
Pacira Pharmaceuticals (PCRX) rose 19.5% and closed at $49.12. Pacira had a weight of 0.25% in IBB’s portfolio. It was one of the top performers on October 27.
XBI’s Moving Averages: The Massive Plummet Last Week
XBI’s moving average took a hit in the week ended September 25, and most of its stocks were trading below all the moving averages. Compared to the previous week, the fall was massive.
Dyax Traded above Its 100-Day Moving Average
Dyax (DYAX) gained 9.41% last week. The stock went up after Dyax presented at the Morgan Stanley global healthcare conference, which took place September 16-18 in New York.
Performance of XBI and IBB with Respective Benchmark Indexes
The SPDR S&P Biotech ETF (XBI) fell 4.53%. It tracks the S&P Biotechnology Select Industry Index as its benchmark index, which fell 4.32% for the week ended September 4.
Pharmaceutical Stocks Affect the iShares NASDAQ Biotechnology ETF
Out of 62 stocks held within the pharmaceutical subgroup of the iShares NASDAQ Biotechnology ETF (IBB), 49 stocks fell during the week ending August 7, 2015.
Moving Average Analysis of the Pharmaceutical Subgroup
For the week ending July 31, the stocks that moved into the 100-day moving average zone include Akorn, Clovis Oncology, Endo International, and Grifols.
